News >

Expert Elaborates on Developments in SCLC and EGFR-Mutant NSCLC

Caroline Seymour
Published: Thursday, Jun 28, 2018

Kathryn A. Gold, MD

Kathryn A. Gold, MD

Data from the phase III FLAURA study cemented osimertinib’s (Tagrisso) place as the frontline standard of care for patients with EGFR-mutation positive non–small cell lung cancer (NSCLC), said Kathryn A. Gold, MD.

-mutant NSCLC and the latest developments in SCLC.

OncLive: Please provide an overview of your presentation.

Gold: As we all know, EGFR-mutant lung cancer is important to recognize clinically because these patients are treated differently. They benefit from TKIs rather than from standard chemotherapy. Until very recently, our standard treatment for patients was erlotinib, afatinib (Gilotrif), or gefitinib in the frontline setting.

-mutant lung cancer. These patients were randomized to osimertinib versus the standard first-generation agents. The results were pretty impressive. Osimertinib clearly had improved PFS and [had] a trend toward improved overall survival [OS]. It’s also a very-well-tolerated drug. Our frontline standard of care has become osimertinib since those data were presented.

Is the future of osimertinib in combination or as a single agent?

Frontline osimertinib is here to stay for now. A 19-month PFS is pretty impressive for a very-well-tolerated drug. It’s tough to imagine frontline combinations coming in and beating [single-agent osimertinib], both in terms of tolerability and outcome.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication